Oncimmune Holdings Plc Stock Current Valuation
| ONC Stock | 15.35 0.20 1.32% |
Valuation analysis of Oncimmune Holdings plc helps investors to measure Oncimmune Holdings' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Oncimmune Holdings' Cash And Short Term Investments are projected to increase significantly based on the last few years of reporting. The current year's Change In Cash is expected to grow to about 1.7 M, whereas Begin Period Cash Flow is forecasted to decline to about 1.6 M. Fundamental drivers impacting Oncimmune Holdings' valuation include:
Price Book 49.2727 | Enterprise Value 21.5 M | Enterprise Value Ebitda (5.12) | Price Sales 14.1327 | Forward PE 76.9231 |
Overvalued
Today
Please note that Oncimmune Holdings' price fluctuation is somewhat reliable at this time. Calculation of the real value of Oncimmune Holdings plc is based on 3 months time horizon. Increasing Oncimmune Holdings' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Oncimmune stock is determined by what a typical buyer is willing to pay for full or partial control of Oncimmune Holdings plc. Since Oncimmune Holdings is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oncimmune Stock. However, Oncimmune Holdings' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.35 | Real 14.16 | Hype 15.35 | Naive 15.93 |
The real value of Oncimmune Stock, also known as its intrinsic value, is the underlying worth of Oncimmune Holdings plc Company, which is reflected in its stock price. It is based on Oncimmune Holdings' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Oncimmune Holdings' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Oncimmune Holdings plc helps investors to forecast how Oncimmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oncimmune Holdings more accurately as focusing exclusively on Oncimmune Holdings' fundamentals will not take into account other important factors: Oncimmune Holdings plc Company Current Valuation Analysis
Oncimmune Holdings' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Oncimmune Holdings Current Valuation | 21.51 M |
Most of Oncimmune Holdings' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncimmune Holdings plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Oncimmune Holdings plc has a Current Valuation of 21.51 M. This is 99.85% lower than that of the Biotechnology sector and 99.54% lower than that of the Health Care industry. The current valuation for all United Kingdom stocks is 99.87% higher than that of the company.
Oncimmune Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncimmune Holdings' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncimmune Holdings could also be used in its relative valuation, which is a method of valuing Oncimmune Holdings by comparing valuation metrics of similar companies.Oncimmune Holdings is currently under evaluation in current valuation category among its peers.
Oncimmune Fundamentals
| Return On Equity | -7.61 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | 5.86 % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 21.51 M | ||||
| Shares Outstanding | 111.77 M | ||||
| Shares Owned By Insiders | 20.33 % | ||||
| Shares Owned By Institutions | 16.50 % | ||||
| Price To Book | 49.27 X | ||||
| Price To Sales | 14.13 X | ||||
| Revenue | 1.15 M | ||||
| Gross Profit | 1.46 M | ||||
| EBITDA | (3.98 M) | ||||
| Net Income | (6.15 M) | ||||
| Total Debt | 5.3 M | ||||
| Cash Flow From Operations | (6.79 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 50.0 | ||||
| Number Of Employees | 38 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 17.16 M | ||||
| Total Asset | 8.44 M | ||||
| Retained Earnings | (42.54 M) | ||||
| Working Capital | 4.14 M | ||||
| Net Asset | 8.44 M |
About Oncimmune Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncimmune Holdings plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncimmune Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncimmune Holdings plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Oncimmune Stock
Oncimmune Holdings financial ratios help investors to determine whether Oncimmune Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncimmune with respect to the benefits of owning Oncimmune Holdings security.